There are currently 208 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Autism participants are California, New York, Ohio and Texas.
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
NCT05396885
Recruiting
A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Honor Health, Scottsdale, Arizona +19 locations
Conditions: Multiple Myeloma
Register for Updates
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03091257
Recruiting
This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: Trametinib Dabrafenib
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Multiple Myeloma
Register for Updates
Elranatamab in R/R Multiple Myeloma
NCT06138275
Recruiting
This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma
Register for Updates
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
NCT04822337
Recruiting
This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and to evaluate the overall response to this study treatment combination.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Levine Cancer Institute, Charlotte, North Carolina
Conditions: Multiple Myeloma
Register for Updates
In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET
NCT05093335
Recruiting
The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Non-Hodgkin Lymphoma, Multiple Myeloma, Histiocytic Neoplasms, Erdheim-Chester Disease, Rosai-Dorfman Disease
Register for Updates
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06215118
Recruiting
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disea... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: MSK Basking Ridge, Basking Ridge, New Jersey +7 locations
Conditions: Multiple Myeloma
Register for Updates
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
NCT05090566
Recruiting
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Banner Gateway Medical Center, Gilbert, Arizona +41 locations
Conditions: Multiple Myeloma
Register for Updates
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
NCT05137054
Recruiting
The study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evide... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: Karmanos Cancer Institute, Detroit, Michigan +31 locations
Conditions: Multiple Myeloma
Register for Updates
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
NCT05065047
Recruiting
The goal of this clinical research study is to learn if belantamab mafodotin (Blenrep) can help to prevent multiple myeloma (MM) from coming back after patients have had an autologous stem cell transplant (AutoSCT). The safety of this drug after transplant will also be studied
Gender:
All
Ages:
18 years and above
Trial Updated:
04/10/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Multiple Myeloma
Register for Updates
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806
Recruiting
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +117 locations
Conditions: Multiple Myeloma
Register for Updates
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
NCT03486067
Recruiting
Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +36 locations
Conditions: Multiple Myeloma
Register for Updates
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016
Recruiting
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Rocky Mountain Cancer Centers, Aurora, Colorado +259 locations
Conditions: Multiple Myeloma
Register for Updates